证券之星消息，截至2024年9月20日收盘，金鹰股份(600232)报收于4.45元，下跌1.98%，换手率0.61%，成交量2.23万手，成交额1000.62万元。 9月20日的资金流向数据方面，主力资金净流出146.81万元，占总成交额14.67 ...

GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody ...

2024年9月17日， Terns（TERN）披露2笔公司内部人交易情况。董事Lu Hongbo于2024年9月12日买入28.57万股。 2024年9月17日 董事 Lu Hongbo 2024年9月12日 买入 47.62万 10.50 500.00万 2024年9月12日 高管 Vignola Mark J. 2024年9月10日 买入 1.00万 5.36 5.36万 2024年9月12日 ...

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.

Cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with previously treated, ...

The median radiographic progression-free survival was 9.5 months with 177Lu-PNT2002 and 6.0 months with an androgen-receptor pathway inhibitor. 177 Lu-PNT2002 can improve progression-free survival ...

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes ...

Not only does lutetium-177-PSMA-617 lower PSA levels in men with metastatic prostate cancer (mCRPC), PSA decline correlates with outcomes, research shows.

A targeted radioactive therapy used to treat late-stage prostate cancer is also effective for patients in the early stages of the disease Australian ...

ANSTO congratulated the Peter Macallum Cancer Centre led team, who recently reported the remarkable results of late-stage ...

A new type of prostate cancer therapy that is used only in late-stage treatment where conventional therapy has failed has ...

A Torquay man who has undergone years of radiation and chemotherapy for prostate cancer is urging other men not to put off a ...